How Cyclodextrin Therapy Is Changing the Outlook for Children With Niemann-Pick Disease

Niemann-Pick Disease Type C1 (NPC1) is a devastating rare genetic disorder that causes cholesterol and lipids to accumulate inside cells, leading to progressive neurological decline. A cyclodextrin-based therapy called Trappsol Cyclo (hydroxypropyl-beta-cyclodextrin) is showing remarkable promise in clinical trials.

In a Phase I/II international study published in Molecular Genetics and Metabolism, 88.9% of patients who completed the 48-week trial showed improvement in at least two clinical domains, with physicians rating 7 out of 9 patients as improved. The results are even more striking in young children.

Preliminary data from the ongoing Phase 3 TransportNPC trial showed that 7 of 9 patients under three years old demonstrated stabilization or improvement after 48 weeks of treatment. The cyclodextrin works by mobilizing trapped cholesterol from lysosomes, directly targeting the root cause of the disease rather than just managing symptoms.

These findings underscore the expanding role of cyclodextrins beyond traditional pharmaceutical excipients into active therapeutic agents capable of addressing unmet medical needs in rare disease.